Idera Pharmact: (NASD: IDRA)
$0.70
0.03 (4.48%)
Volume 13,331
May 17 03:59 PM ET
Zacks Rank: NA 
| |
Overview Quote
Stock Activity
| Day Low - High | 0.70 - 0.74 |
| 52wk Low - High | 0.19 - 1.22 |
| Previous Close | 0.67 |
| Avg. Volume | 371,418 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 19.35 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.71 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.81 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
|
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
91 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.81 |
| Current Quarter Estimate | -0.20 |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-08-2013 |
| EPS Last Year | -0.72 |
| Expected Earnings Growth | NA |
Company Description
Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera's proprietary drug candidates are designed to modulate Toll-like Receptors, the body's first line of immune defense. Idera's pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (ND) |
Next Qtr (ND) |
Current Year (ND) |
Next Year (ND) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | NA | NA |
| Number of Estimates | NA | NA | NA | NA |
| Low Estimate | NA | NA | NA | NA |
| High Estimate | NA | NA | NA | NA |
| Year Ago EPS | NA | NA | NA | NA |
| EPS Growth | NA | NA | NA | NA |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| AETERNA ZENTARS | AEZS | 2.10 | |
|
| ANIKA THERAPEUT | ANIK | 14.40 | |
|
| GENTIUM SPA-ADR | GENT | 8.87 | |
|
| AASTROM BIOSCI | ASTM | 0.57 | |
|
| ACHILLION PHARM | ACHN | 7.77 | |
|
| ADDEX THERA LTD | ADDXF | 6.94 | |
|
| AFFYMAX INC | AFFY | 1.33 | |
|
| ALEXION PHARMA | ALXN | 102.90 | |
|
| ALKERMES INC | ALKS | 31.69 | |
|
| ALNYLAM PHARMA | ALNY | 27.44 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Financials
| EPS TTM | -0.72 |
| Sales | 0 |
| Net Income | -16 |
| Price/Earnings | NA |
| Price/Book | NA |
| Price/Cash Flow | NA |
| Price/Sales | 394.90 |
News
Idera Pharmaceuticals Reports First Quarter 2013 Financial Results - Businesswire
May 15, 2013
Idera Pharmaceuticals, Inc.Corporate Event Announcement Notice - Wall Street Horizon
May 14, 2013
Stock to Watch: Idera Pharmaceuticals Up 7.8% (IDRA) - Financial News Network Online - Market Movers
May 14, 2013
Traders Get Bullish on Shares of Idera Pharmaceuticals, Shares Up 7.8% (IDRA) - Comtex Smartrend(R)
May 14, 2013
Idera Pharmaceuticals, Inc.Corporate Event Announcement Notice - Wall Street Horizon
May 13, 2013
Idera Pharmaceuticals Closes Common Share Offering - Close-Up Media
May 12, 2013
Idera Presents Positive Data from Phase 2 Trial of TLR 7 and 9 Antagonist in Patients with Moderate-to-Severe Plaque Psoriasis - Close-Up Media
May 12, 2013
Idera Pharmaceuticals, Inc.Corporate Event Announcement Notice - Wall Street Horizon
May 11, 2013
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 1 |
| Average Target Price | 1.40 |
| Industry Rank by ABR | 91 out of 265 |
| Rank in Industry | NA |
